Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

Por Jackson, Doreen O., Byrd, Kevin, Vreeland, Timothy J., Hale, Diane F., Herbert, Garth S., Greene, Julia M., Schneble, Erika J., Berry, John S., Trappey, Alfred F., Travis Clifton, Guy, Hardin, Mark O., Martin, Jonathan, Elkas, John C., Conrads, Thomas P., Darcy, Kathleen M., Hamilton, Chad A., Maxwell, George L., Peoples, George E.
Publicado no Oncotarget (2016)